GlassScriptPhysician profile
Grant A Anderson
NPI 1578558946
$1,662.50
in general payments reported to CMS, 2019-2025
23 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $448 · 2023: $379 · 2024: $248 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $484.04 | 2021-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $281.47 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $196.48 | 2023-2025 | |
| Pfizer INC. | $128.43 | 2021-2025 | |
| Mylan Specialty L.P. | $91.98 | 2021-2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $67.68 | 2022-2024 | |
| Lilly USA, LLC | $65.13 | 2021-2023 | Jardiance |
| Viatris Specialty LLC | $55.82 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.02 | 2021-2025 | Jardiance |
| Forte Bio-Pharma LLC | $29.24 | 2023-2024 | Prolate, Nalocet |
| Kowa Pharmaceuticals America, INC. | $22.99 | 2021 | |
| Biogen, INC. | $22.26 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.42 | 2024 | Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.90 | 2025 | Caplyta |
| Acadia Pharmaceuticals INC | $18.29 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $16.81 | 2022 | |
| Melinta Therapeutics, LLC | $16.32 | 2022 | |
| Vanda Pharmaceuticals INC. | $15.81 | 2024 | Fanapt, Hetlioz |
| Biohaven Pharmaceutical Holding Company LTD. | $15.53 | 2022 | |
| Glaxosmithkline, LLC. | $15.12 | 2022 | |
| Phadia US INC. | $14.57 | 2025 | Immunocap |
| Paratek Pharmaceuticals, INC. | $13.18 | 2022 | |
| Merck Sharp & Dohme LLC | $13.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.